Michael R. Mattern

8.5k citations

107 papers · 7.0k indexed · h-index 46

Impact in

Toxicology top 0.1%
- Bioactive Compounds and Antitumor Agents
Oncology top 1%
- Lung Cancer Research Studies
- Cancer-related Molecular Pathways

Papers in

Molecular Biology 94
- Cancer therapeutics and mechanisms 32
- DNA Repair Mechanisms 29
- Ubiquitin and proteasome pathways 28
- DNA and Nucleic Acid Chemistry 15
- Protein Degradation and Inhibitors 10
Oncology 35
- Peptidase Inhibition and Analysis 12
- Cancer-related Molecular Pathways 10

Co-authors: Randall K. Johnson Christopher K. Mirabelli Tauseef R. Butt F H Drake Richard Woessner Stanley T. Crooke Glenn A. Hofmann Benjamin Nicholson
Journals: Journal of Natural Products (9 papers)Biochemistry (5 papers)Journal of Medicinal Chemistry (3 papers)Cancer Research (3 papers)SLAS DISCOVERY (3 papers)
Partner nations: United States United Kingdom Australia

In The Last Decade

Michael R. Mattern

106 papers receiving 6.6k citations

Peers

Countries citing papers authored by Michael R. Mattern

Since Specialization

Citations

This map shows the geographic impact of Michael R. Mattern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. Mattern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. Mattern more than expected).

Fields of papers citing papers by Michael R. Mattern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael R. Mattern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. Mattern. The network helps show where Michael R. Mattern may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael R. Mattern, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael R. Mattern Line = papers co-authored together Michael R. Mattern links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Ubiquitin Proteasome System as a Therapeutic Area in Parkinson’s Disease NeuroMolecular Medicine ·Suresh Kumar, Michael R. Mattern, Matthew S. Goldberg, Tauseef R. Butt	2023	8
2	Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+ T-regulatory cells by promoting ubiquitination of Tip60 PLoS ONE ·Feng Wang, Liqing Wang, Jian Wu, 苏永乐, Phuong Nguyen, Elena Herreros Tabernero, Joseph Weinstock, Michael R. Mattern, Irina Bezsonova, Wayne W. Hancock, Suresh Kumar	2017	42
3	Chemical Approaches to Intervening in Ubiquitin Specific Protease 7 (USP7) Function for Oncology and Immune Oncology Therapies Journal of Medicinal Chemistry ·Jian Wu, Suresh Kumar, Feng Wang, Hui Wang, Lijia Chen, Noppakorn Prakansamut, Michael R. Mattern, Joseph Weinstock	2017	38
4	Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives SLAS DISCOVERY ·Benjamin Nicholson, Suresh Kumar, Saket Agarwal, Michael J. Eddins, Jeffrey G. Marblestone, Jian Wu, Matthew P. Kodrasov, Jo Ann Rupert, David E. Sterner, Michael R. Mattern	2014	10
5	Comprehensive Ubiquitin E2 Profiling of Ten Ubiquitin E3 Ligases Cell Biochemistry and Biophysics ·Jeffrey G. Marblestone, Yun-feng Mao, Tu ErDi, David E. Sterner, Michael R. Mattern, Benjamin Nicholson, Michael J. Eddins	2013	22
6	Ubiquitin-based anticancer therapy: Carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Michael R. Mattern, Jian Wu, Benjamin Nicholson	2012	56
7	Analysis of ubiquitin E3 ligase activity using selective polyubiquitin binding proteins Biochimica et Biophysica Acta (BBA) - Molecular Cell Research ·Jeffrey G. Marblestone, Jo Ann Rupert, Michael R. Mattern, Craig A. Leach	2012	16
8	Characterization of Selective Ubiquitin and Ubiquitin-Like Protease Inhibitors Using a Fluorescence-Based Multiplex Assay Format Assay and Drug Development Technologies ·Xufan Tian, F.F. Shue, Raymond J. Peroutka, Seth J. Goldenberg, Michael R. Mattern, Benjamin Nicholson, Craig A. Leach	2010	67
9	Characterization of ubiquitin and ubiquitin‐like‐protein isopeptidase activities Protein Science ·Benjamin Nicholson, Craig A. Leach, Seth J. Goldenberg, Dana M. Francis, Matthew P. Kodrasov, Xufan Tian, John Shanks, David E. Sterner, Alejandro Bernal, Michael R. Mattern, Keith D. Wilkinson, Tauseef R. Butt	2008	115
10	Detection and Characterization of SUMO Protease Activity Using a Sensitive Enzyme-Based Reporter Assay Methods in molecular biology ·Craig A. Leach, Xufan Tian, Michael R. Mattern, Benjamin Nicholson	2008	9
11	Small ubiquitin-like modifying protein isopeptidase assay based on poliovirus RNA polymerase activity Analytical Biochemistry ·Jamie J. Arnold, Alejandro Bernal, Uzodinma Uche, David E. Sterner, Tauseef R. Butt, Craig E. Cameron, Michael R. Mattern	2005	24
12	SUMO fusion technology for difficult-to-express proteins Protein Expression and Purification ·Tauseef R. Butt, Suzanne C. Edavettal, Syamimi Samah, Michael R. Mattern	2005	381
13	Expression and purification of SARS coronavirus proteins using SUMO-fusions Protein Expression and Purification ·X Zuo, Michael R. Mattern, Florian Beutler, Neel Choksi, Syamimi Samah, David E. Sterner, L. Hayflick, Hiep T. Tran, Peter A.C. Lim, Stefan G. Sarafianos, 雅徳森本, Sonia Navas, Susan R. Weiss, Tauseef R. Butt	2005	68
14	The Identification and Characterization of the Marine Natural Product Scytonemin as a Novel Antiproliferative Pharmacophore Journal of Pharmacology and Experimental Therapeutics ·Christopher S. Stevenson, Mario Michaud, Amy Roshak, Brian L. Márquez, R. Pavanello, Jeffrey R. Jackson, Michael R. Mattern, William H. Gerwick, Robert S. Jacobs, Lisa A. Marshall	2002	148
15	Amphibian Melanophore Technology as a Functional Screen for Antagonists of G-Protein Coupled 7-Transmembrane Receptors SLAS DISCOVERY ·Mark Nuttall, John C. Lee, Paul R. Murdock, Alison M. Badger, Feilan Wang, Jeffrey T. Laydon, Glenn A. Hofmann, Gary Pettman, Jonathan A. Lee, Arpana Parihar, Bradford C. Van Wagenen, John Fox, Maxine Gowen, А. П. Трухан, Michael R. Mattern	1999	4
16	Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway Oncogene ·Priya Chaturvedi, N. S. Filipsky, Yuan Zhu, Michael R. Mattern, Fernando Ulpiano Pantoja-Agreda, Mark R. Hurle, Xiaolong Zhang, Roland S. Annan, Quinn Lu, Leo F. Faucette, Gilbert Scott, Xiaotong Li, Steven A. Carr, Randall K. Johnson, James D. Winkler, Bin‐Bing S. Zhou	1999	345
17	Effect of specific enzyme inhibitors on replication, total genome DNA repair and on gene-specific DNA repair after UV irradiation in CHO cells Mutation Research/DNA Repair ·Jennifer Jones, Tinna Stevnsner, Michael R. Mattern, Vilhelm A. Bohr	1991	19
18	Inhibition of endothelin‐mediated topoisomerase I activation by pertussis toxin FEBS Letters ·P Nambi, Hsiao-Ling Wu, Richard Woessner, Michael R. Mattern	1990	4
19	Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II Biochemistry ·Fred H. Drake, Glenn A. Hofmann, H F Bartus, Michael R. Mattern, Stanley T. Crooke, Christopher K. Mirabelli	1989	362
20	Nucleoid sedimentation analysis of DNA strand breaks induced in cells exposed to DNA intercalating agents Pharmacology & Therapeutics ·Michael R. Mattern, Donna Kerrigan, Yves Pommier	1987	10

About Michael R. Mattern

Michael R. Mattern is a scholar working on Molecular Biology, Oncology, Toxicology, Biotechnology and Cancer Research, having authored 107 papers that have together received 7.0k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (32 papers), DNA Repair Mechanisms (29 papers), Ubiquitin and proteasome pathways (28 papers), DNA and Nucleic Acid Chemistry (15 papers), Peptidase Inhibition and Analysis (12 papers), Cancer-related Molecular Pathways (10 papers), Protein Degradation and Inhibitors (10 papers) and Synthesis and Biological Evaluation (8 papers). The work is most often cited by research in Toxicology (653 citations), Oncology (2.6k citations), Molecular Biology (5.8k citations), Cancer Research (610 citations) and Biotechnology (266 citations). Michael R. Mattern has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Randall K. Johnson, Christopher K. Mirabelli, Tauseef R. Butt, F H Drake, Richard Woessner, Stanley T. Crooke, Glenn A. Hofmann, Benjamin Nicholson, Dominic A. Scudiero and G A Hofmann. Their work appears in journals such as Journal of Natural Products, Biochemistry, Journal of Medicinal Chemistry, Cancer Research and SLAS DISCOVERY.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact